IRIS
VITA, GIANLUCA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 7.490
NA - Nord America 7.196
AS - Asia 4.338
SA - Sud America 1.387
Continente sconosciuto - Info sul continente non disponibili 382
AF - Africa 131
OC - Oceania 11
Totale 20.935
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.971
RU - Federazione Russa 3.824
SG - Singapore 1.962
BR - Brasile 1.179
CN - Cina 1.165
IE - Irlanda 902
IT - Italia 658
SE - Svezia 603
HK - Hong Kong 385
PL - Polonia 334
DE - Germania 289
VN - Vietnam 286
FR - Francia 285
FI - Finlandia 178
GB - Regno Unito 166
IN - India 128
CA - Canada 89
BD - Bangladesh 88
UA - Ucraina 83
AR - Argentina 77
MX - Messico 56
TR - Turchia 45
IQ - Iraq 43
ZA - Sudafrica 38
ID - Indonesia 37
BE - Belgio 32
AT - Austria 30
EC - Ecuador 30
CI - Costa d'Avorio 28
JP - Giappone 28
VE - Venezuela 26
CO - Colombia 25
NL - Olanda 25
PK - Pakistan 22
MA - Marocco 19
CR - Costa Rica 18
ES - Italia 18
CL - Cile 16
KE - Kenya 15
UZ - Uzbekistan 15
JM - Giamaica 14
LT - Lituania 14
MY - Malesia 13
PH - Filippine 13
SA - Arabia Saudita 13
CZ - Repubblica Ceca 12
HN - Honduras 12
AE - Emirati Arabi Uniti 11
PE - Perù 11
JO - Giordania 10
PY - Paraguay 10
TN - Tunisia 10
EU - Europa 9
IL - Israele 9
AZ - Azerbaigian 8
KZ - Kazakistan 8
NP - Nepal 8
AU - Australia 7
EG - Egitto 7
NI - Nicaragua 6
RO - Romania 6
TT - Trinidad e Tobago 6
UY - Uruguay 6
DO - Repubblica Dominicana 5
OM - Oman 5
GT - Guatemala 4
GY - Guiana 4
KW - Kuwait 4
NZ - Nuova Zelanda 4
PA - Panama 4
SK - Slovacchia (Repubblica Slovacca) 4
SV - El Salvador 4
BO - Bolivia 3
BY - Bielorussia 3
CY - Cipro 3
EE - Estonia 3
HU - Ungheria 3
IR - Iran 3
KR - Corea 3
LB - Libano 3
PR - Porto Rico 3
TH - Thailandia 3
XK - ???statistics.table.value.countryCode.XK??? 3
AL - Albania 2
AO - Angola 2
CW - ???statistics.table.value.countryCode.CW??? 2
GA - Gabon 2
KG - Kirghizistan 2
LK - Sri Lanka 2
MD - Moldavia 2
PS - Palestinian Territory 2
PT - Portogallo 2
RS - Serbia 2
SN - Senegal 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BH - Bahrain 1
BM - Bermuda 1
Totale 20.540
Salva come PNG Salva come JPEG
Città #
Ashburn 1.143
Moscow 1.121
Dublin 901
Singapore 814
Chandler 615
Dallas 593
San Jose 440
Beijing 429
Hong Kong 385
Nyköping 377
Warsaw 322
Council Bluffs 268
Jacksonville 241
The Dalles 221
Princeton 176
Messina 147
Los Angeles 142
Medford 140
Lauterbourg 137
Ann Arbor 135
Cambridge 115
Ho Chi Minh City 101
New York 99
Munich 92
Des Moines 91
São Paulo 84
Buffalo 69
Boardman 63
Dearborn 62
Lancaster 59
Bremen 58
Tianjin 58
Shenyang 57
Pune 53
Santa Clara 53
San Mateo 49
Turku 47
Frankfurt am Main 46
Orem 46
Rome 46
Hanoi 45
Wilmington 45
Houston 43
Jinan 42
Rio de Janeiro 42
Redondo Beach 41
Atlanta 36
Belo Horizonte 32
Nanjing 31
Brooklyn 30
Brussels 30
Abidjan 28
Guangzhou 28
Milan 27
Tokyo 25
Chennai 24
Phoenix 24
Porto Alegre 24
Hebei 23
Curitiba 22
Hangzhou 22
Helsinki 22
Ningbo 22
Brasília 21
Montreal 21
Zhengzhou 21
Dong Ket 20
Toronto 20
Baghdad 19
Amsterdam 17
London 17
North Bergen 17
Catania 16
Seattle 16
Woodbridge 16
Denver 15
Johannesburg 15
Shanghai 15
Stockholm 15
Chicago 14
Jakarta 14
Nuremberg 14
Salvador 14
Tashkent 14
Vienna 14
Changsha 13
Manchester 13
Mexico City 13
Palo Del Colle 13
San José 13
Taizhou 13
Dhaka 12
Guarulhos 12
Nanchang 12
Quito 12
San Francisco 12
Campinas 11
Haikou 11
Hyderabad 11
Istanbul 11
Totale 11.350
Salva come PNG Salva come JPEG
Nome #
6MWT performance correlates with peripheral neuropathy but not with cardiac involvement in patients with hereditary transthyretin amyloidosis (hATTR) 345
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 297
A Phase 1/2 Study of Flavocoxid, an Oral NF-κB Inhibitor, in Duchenne Muscular Dystrophy 266
Psychosocial impact of presymptomatic genetic testing for amyloidotic polyneuropathy 262
Clinical and pathological features of focal myositis 257
Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventions 252
Integrated care of muscular dystrophies in Italy. Part 2. Psychological treatments, social and welfare support, and financial costs 244
Circulating miRNAs expression as potential biomarkers of mild traumatic brain injury 231
Circulating microRNAs Profile in Patients With Transthyretin Variant Amyloidosis 227
24 month longitudinal data in ambulant boys with Duchenne muscular dystrophy. 224
Anabolic treatment with RHPTH of duchenne muscular dystrophy related osteoporosis: a case report 212
Nusinersen versus sham control in later-onset spinal muscular atrophy 212
Health-related quality of life and functional changes in DMD: A 12-month longitudinal cohort study 207
Which are the factors influencing NIV adaptation and tolerance in ALS patients? 207
microRNA-10 and -221 modulate differential expression of Hippo signaling pathway in human astroglial tumors 207
Dolori muscolari, deficit di forza e/o disturbi sensitivi 203
Modulation of neuronal nitric oxide synthase and apoptosis by the isoflavone genistein in Mdx mice 201
Effect of exercise on telomere length and telomere proteins expression in mdx mice 199
Hippo signaling pathway is altered in Duchenne muscular dystrophy 197
Emergenze respiratorie nelle malattie neurologiche 197
Autonomic nervous system involvement in spinal muscular atrophy. 196
Parenteral nutrition improves nutritional status, autonomic symptoms and quality of life in transthyretin amyloid polyneuropathy 193
Benefits of glucocorticoids in non-ambulant boys/men with Duchenne muscular dystrophy: A multicentric longitudinal study using the Performance of Upper Limb test 190
6 Minute Walk Test in Duchenne MD Patients with Different Mutations: 12 Month Changes 188
Intrathecal administration of Nusinersen in type 1 SMA: successful psychological program in a single Italian center 188
ANT1 is reduced in sporadic inclusion body myositis. 185
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 1: peripheral neuropathies 179
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis. 178
Pilot study of flavocoxid in ambulant DMD patients. 178
Pilot study of serial casting in muscular dystrophy patients. 177
Pilot study of serial casting of ankles in muscular dystrophy patients. 176
Parenteral nutrition improves nutritional status, autonomic symptoms and qol in patients with TTR-FAP 175
Neuropsychological patter in centronuclear myopathy due to DNM2 gene mutations. 174
Activation of NF-kappaB pathway in Duchenne muscular dystrophy: relation to age 174
Modulation of neural nitric oxide synthase by the isoflavone genistein promotes muscle regeneration in mdx mice 171
Psycological status and emotional burden in amyotrophic lateral sclerosis caregivers: the role of metacognitive processes. 169
Bone health in Duchenne muscular dystrophy: clinical and biochemical correlates 169
Impaired myocardial strain in early stage of Duchenne muscular dystrophy: its relation with age and motor performance 168
Predictors of adaptation to non-invasive ventilation in amyotrophic lateral sclerosis 167
Impaired myocardial deformation revealing subclinical left ventricular dysfunction in children with Duchenne dystrophy: a speckle tracking echocardiography study 164
Dolori muscolari, deficit di forza e/o disturbi sensitivi 164
Psychosocial impact of sport activity in neuromuscular disorders 164
Novel outcome measures for Charcot-Marie-Tooth disease: Validation and reliability of the 6-min walk test and StepWatch™ Activity Monitor and identification of the walking features related to higher quality of life 162
Predictors of adaptation to non-invasive ventilation in neuromuscular disorders. 161
Outcome measures in Duchenne muscular dystrophy: validation of the Pediatric Quality of Life InventoryTM Neuromuscular Module in the Italian population and correlation with other functional assessments. 161
Long term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes 159
The 24-month PUL changes and steroids correlation. 159
Pilot study of flavocoxid in ambulant DMD patients. 157
Burden, professional support, and social network in families of children and young adults with muscular dystrophies 157
Pilot study of flavocoxid in ambulant DMD patients. 157
Genetic Modifiers of Duchenne Muscular Dystrophy and Dilated Cardiomyopathy 156
BONE INVOLVEMENT IN DUCHENNE MUSCULAR DYSTROPHY 156
Telomere shortening is associated to TRF1 and PARP1 overexpression in Duchenne muscular dystrophy 156
Severe rhabdomyolysis in a patient with “Heat Stroke” 155
Cardiac function in types II and III spinal muscular atrophy: should we change standards of care? 155
Clinical variability in spinal muscular atrophy type III 155
Practical approach to respiratory emergencies in neurological diseases 154
ANT1 expression and RAGE-NF-kB pathway in sporadic inclusion body myositis 154
Effects of teriparatide on bone mineral density and quality of life in Duchenne muscular dystrophy related osteoporosis: a case report 153
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 152
Burden, social network and professional support in the families of patients with muscular dystrophies: results from the GUP10002 study. 152
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report. 151
Sport activity in Charcot-Marie-Tooth disease: A case study of a Paralympic swimmer 148
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with Duchenne muscular dystrophy: a skeckle tracking study. 148
Telomere shortening and telomere-associated proteins in Duchenne muscular dystrophy. 146
Histological effects of givinostat in boys with Duchenne muscular dystrophy 143
Timed rise from floor as a predictor of disease progression in Duchenne muscular dystrophy: An observational study 143
Teriparatide (rhPTH 1-34) in Duchenne Muscular Dystrophy related osteoporosis: a case report 143
Selective short-term verbal memory involvement in two siblings carrying centronuclear myopathy due to DNM2 gene mutations 142
First report of a family with a DMD out of frame exon 2 deletion associated with asymptomatic phenotypes. 142
Teriparatide (rhPTH) treatment in Duchenne Muscular Dystrophy, a case report. 142
Genetic neuromuscular disorders: living the era of a therapeutic revolution. Part 2: diseases of motor neuron and skeletal muscle 142
Espressione di ANT1 e attivazione della via RAGE-NF-kB nella miosite a corpi inclusi. 141
6 min walking test 12 month changes in DMD: Correlation with genotype. 139
Implication of SIRT1 and its downstream pathways in dystrophic process. 139
Muscle Fat-Fraction and Mapping in Duchenne Muscular Dystrophy: Evaluation of Disease Distribution and Correlation with Clinical Assessments: A preliminary experience. 138
Amyloid myopathy presenting with rhabdomyolysis. 137
study of flavocoxid in ambulant DMD patients. 137
Respiratory Emergencies in Neurological Diseases 137
MYH7-related myopathies: Clinical, histopathological and imaging findings in a cohort of Italian patients 134
Impaired rotational mechanics and strain revealing subclinical left ventricular dysfunction in children with neuromuscolar disorders: a speckle tracking study 133
Bone quality in Duchenne muscular dystrophy 131
The soy isoflavone genistein blunts nuclear factor kappa-B, MAPKs and TNF-α activation and ameliorates muscle function and morphology in mdx mice. 128
Dual-echo dual flip angle gradient-echo MRI technique for quantification of muscle fat fraction in Duchenne muscular dystrophy: a new valuable outcome measure. 127
Telomere shortening and telomere associated proteins in exercised wild type and mdx mice. 127
Pilot study of flavocoxid in ambulant DMD patients. 127
The 6 minute walk test and performance of upper limb in ambulant duchenne muscular dystrophy boys 126
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy 125
Flavocoxid counteracts muscle necrosis and improves functional properties in mdx mice: a comparison study with methylprednisolone 124
Reliability of the Performance of Upper Limb assessment in Duchenne muscular dystrophy 123
Psychological and practical difficulties among parents and healthy siblings of children with Duchenne vs. Becker muscular dystrophy: an Italian comparative study 121
Miopatia prossimale in paziente con sindrome di Williams 117
Role of calcineurin/NFAT on muscle regeneration in dystrophic process. 117
Safety and effectiveness of ataluren: comparison of results from the STRIDE Registry and CINRG DMD Natural History Study 110
Psychosocial impact of presymptomatic genetic testing for transthyretin amyloidotic polyneuropathy 109
Longitudinal natural history in young boys with Duchenne muscular dystrophy 109
The Genetic Landscape of Dystrophin Mutations in Italy: A Nationwide Study 107
Pilot study of flavocoxid in ambulant DMD patients. 106
FSHD and Williams syndrome: the occurrence of two genetic disorders due to heterozygous DNA fragment deletions in the same patient. 104
The first report of a patient carrying an out-of-frame exon2 deletion in the dystrophin gene and showing a very unusual phenotype. 104
Totale 16.572
Salva come PNG Salva come JPEG
Categoria #
all - tutte 71.700
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 71.700
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022838 0 0 0 64 48 6 94 37 33 91 88 377
2022/20232.391 195 227 125 158 202 197 18 114 1.081 6 57 11
2023/2024724 31 114 35 82 52 174 35 41 5 32 25 98
2024/20253.384 61 45 39 190 91 84 76 640 721 188 537 712
2025/20269.278 471 615 701 677 724 1.858 1.112 1.122 1.202 420 188 188
2026/20271.681 195 611 365 510 0 0 0 0 0 0 0 0
Totale 20.935